You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameXylometazoline
Accession NumberDB06694
TypeSmall Molecule
GroupsApproved
DescriptionA nasal vasoconstricting decongestant drug which acts by binding to the same receptors as adrenaline. It is applied as a spray or as drops into the nose to ease inflammation and congestion of the nasal passageways. It binds alpha-adrenergic receptors to activate the adrenal system which causes systemic vasoconstriction, thereby easing nasal congestion.
Structure
Thumb
Synonyms
Balminil
Xylomethazoline
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
4 Way Moisturizing ReliefSpray.01 L/LNasalNovartis Consumer Health, Inc.2010-01-01Not applicableUs
Aqua Maris Fast Acting DecongestantSpray10 mg/10mLNasalJgl North America Llc2012-12-15Not applicableUs
Aqua Maris Kids Fast Acting DecongestantSpray.05 mg/10mLNasalJgl North America Llc2010-09-27Not applicableUs
Balminil DecongestSolution0.1 %NasalTeva Canada Limited2007-12-14Not applicableCanada
Balminil Nasal DecongestantSpray0.1 %NasalTeva Canada Limited1997-08-26Not applicableCanada
Certified Decongestant Nasal Spray .1%Solution; Spray0.1 %NasalProdemdis Enr.1996-09-192010-07-15Canada
Cold & Allergy ReliefSpray0.1 %NasalPharmascience Inc2003-02-01Not applicableCanada
Cold & Allergy Relief With MoisturizersSpray0.1 %NasalPharmascience Inc2003-02-01Not applicableCanada
Cold and Allergy Decongestant Nasal SpraySpray0.1 %NasalTeva Canada Limited2011-10-01Not applicableCanada
Decongest NasalSolution0.1 %NasalTeva Canada Limited2007-12-20Not applicableCanada
Decongestant Nasal SpraySpray0.1 %NasalJamp Pharma Corporation2005-01-31Not applicableCanada
Decongestant Nasal SpraySpray0.1 %NasalCrlsNot applicableNot applicableCanada
Decongestant Nasal Spray - 0.10%Liquid; Spray.1 %NasalWes Pak Products Ltd.1998-01-142000-08-04Canada
Decongestant Nasal Spray 0.1%Solution; Spray.1 %NasalProdemdis Enr.1996-09-192008-08-08Canada
Decongestant Nasal Spray 0.1%Spray.1 %NasalTeva Canada Limited1993-12-31Not applicableCanada
Decongestant Nasal Spray 0.1% USPSpray.1 %NasalKsl Pharmaceuticals1992-12-311996-09-09Canada
Decongestant Nasal Spray 0.1% W/VSpray.1 %NasalStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Decongestant Nasal Spray With MoisturizersSpray0.1 %NasalJamp Pharma Corporation2005-01-31Not applicableCanada
Decongestant Nose Drops 0.1%Solution / drops0.1 %NasalLaboratoires Confab Inc1991-12-31Not applicableCanada
Nasal Decongestant Spray With MoisturizersSpray0.1 %NasalCrlsNot applicableNot applicableCanada
Nasal Decongestant Spray With MoisturizersSpray0.1 %NasalLaboratoires Confab Inc2000-11-11Not applicableCanada
Otrivin Allergy and Cold Decongestant Nasal SpraySpray0.05 %NasalGlaxosmithkline Consumer Healthcare Inc.1999-08-09Not applicableCanada
Otrivin Cold and Allergy Decongestant Nose DropsSolution0.1 %NasalGlaxosmithkline Consumer Healthcare Inc.1960-12-31Not applicableCanada
Otrivin Decongestant Nose Drops 0.05%Solution / drops0.05 %NasalNovartis Consumer Health Canada Inc.1999-11-122007-03-23Canada
Otrivin Medicated Cold & Allergy ReliefSpray0.1 %NasalGlaxosmithkline Consumer Healthcare Inc.1961-12-31Not applicableCanada
Otrivin Medicated Cold & Allergy Relief With MoisturizersSpray0.1 %NasalGlaxosmithkline Consumer Healthcare Inc.1996-10-15Not applicableCanada
Otrivin Medicated Complete Nasal CareSpray0.1 %NasalGlaxosmithkline Consumer Healthcare Inc.2010-08-02Not applicableCanada
Otrivin Menthol - Asp-liq 0.1%Liquid; Spray.1 %NasalNovartis Consumer Health Canada Inc.1994-12-312009-06-29Canada
Otrivin Pediatric Decongestant Nose DropsSolution / drops.05 %NasalNovartis Consumer Health Canada Inc.1960-12-312000-01-18Canada
Otrivin Pediatric Nasal Spray 0.05%Spray.05 %NasalNovartis Consumer Health Canada Inc.1985-12-311999-07-21Canada
Otrivin Sinus ReliefSolution0.1 %NasalGlaxosmithkline Consumer Healthcare Inc.Not applicableNot applicableCanada
Otrivin With M-D PumpSpray.1 %NasalNovartis Consumer Health Canada Inc.1987-12-312009-06-29Canada
Sinosil Nasal DecongestantSpray.015 mL/15mLNasalHerbion Pakistan Pvt Ltd2011-02-09Not applicableUs
Vaporisateur Nasal DecongestionnantSolution0.1 %NasalLaboratoires Confab Inc1991-12-31Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
OtrivenNot Available
OtrivinNot Available
OtrivineNot Available
OtrixNot Available
XylometNot Available
XylostarIntas
Brand mixtures
NameLabellerIngredients
Ophtrivin A Ophthalmic DpsCiba Vision Canada Inc
Salts
Name/CASStructureProperties
Xylometazoline hydrochloride
ThumbNot applicableDBSALT001557
Categories
UNIIWPY40FTH8K
CAS number526-36-3
WeightAverage: 244.3752
Monoisotopic: 244.193948778
Chemical FormulaC16H24N2
InChI KeyHUCJFAOMUPXHDK-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
IUPAC Name
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
SMILES
CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C
Pharmacology
IndicationIt is used for treating nasal congestion and minor inflammation due to allergies or colds.
Structured Indications
PharmacodynamicsXylometazoline is a direct acting sympathomimetic adrenergic alpha-agonist used to induce systemic vasoconstriction, thereby decreasing nasal congestion. The sympathomimetic action of xylometazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (8-12 hours) decongesting effect.
Mechanism of actionXylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-1A adrenergic receptorProteinyes
agonist
HumanP35348 details
Alpha-2A adrenergic receptorProteinyes
agonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinyes
agonist
HumanP18089 details
Alpha-1B adrenergic receptorProteinunknown
agonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknown
agonist
HumanP25100 details
Alpha-2C adrenergic receptorProteinunknown
agonist
HumanP18825 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Xylometazoline.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Xylometazoline.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Xylometazoline.Experimental
AcebutololXylometazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
AliskirenXylometazoline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanXylometazoline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineXylometazoline may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineAmineptine may decrease the antihypertensive activities of Xylometazoline.Illicit, Withdrawn
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Xylometazoline.Approved
AmobarbitalThe metabolism of Xylometazoline can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Xylometazoline.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Xylometazoline.Approved, Investigational
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Xylometazoline.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Xylometazoline.Approved, Investigational
Aop200704Xylometazoline may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ArotinololXylometazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Xylometazoline.Approved
AtenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Atosiban.Approved
Atracurium besylateXylometazoline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Xylometazoline.Experimental
BarbexacloneThe metabolism of Xylometazoline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Xylometazoline can be increased when combined with Barbital.Illicit
BefunololXylometazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilBenazepril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Xylometazoline.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Xylometazoline.Approved
BepridilBepridil may increase the hypotensive activities of Xylometazoline.Approved, Withdrawn
BetaxololXylometazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Xylometazoline.Approved
BevantololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Xylometazoline.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BisoprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BosentanBosentan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Xylometazoline.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Xylometazoline.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Xylometazoline.Approved
BucindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolXylometazoline may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Xylometazoline.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Xylometazoline.Approved
CalciumThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CandesartanCandesartan may increase the hypotensive activities of Xylometazoline.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Xylometazoline.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Xylometazoline.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Xylometazoline.Approved
CarbomycinThe metabolism of Xylometazoline can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Xylometazoline.Withdrawn
CarteololXylometazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolXylometazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Xylometazoline.Approved
CeliprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Xylometazoline.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Xylometazoline.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Xylometazoline.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Xylometazoline.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Xylometazoline.Approved
CimetidineThe serum concentration of Xylometazoline can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Xylometazoline can be decreased when combined with Clarithromycin.Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Xylometazoline.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Xylometazoline.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Xylometazoline.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Xylometazoline.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Xylometazoline.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Xylometazoline.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Xylometazoline.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Xylometazoline.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Xylometazoline.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Xylometazoline.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Xylometazoline.Experimental
DeserpidineXylometazoline may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Xylometazoline.Approved
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Xylometazoline.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Xylometazoline.Approved
DihydralazineXylometazoline may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Xylometazoline.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Xylometazoline.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Xylometazoline.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Xylometazoline.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Xylometazoline.Approved
DuloxetineDuloxetine may decrease the antihypertensive activities of Xylometazoline.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Xylometazoline.Approved
EfavirenzThe serum concentration of Xylometazoline can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Xylometazoline.Approved
EfonidipineXylometazoline may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
EnalaprilatXylometazoline may increase the hypotensive activities of Enalaprilat.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Xylometazoline.Approved
EprosartanEprosartan may increase the hypotensive activities of Xylometazoline.Approved
ErythromycinThe metabolism of Xylometazoline can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Xylometazoline.Investigational
EsmololXylometazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
FelodipineFelodipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Xylometazoline.Approved
FluconazoleThe serum concentration of Xylometazoline can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Xylometazoline.Approved
FosinoprilFosinopril may increase the hypotensive activities of Xylometazoline.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Xylometazoline.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Xylometazoline.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Xylometazoline.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Xylometazoline.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Xylometazoline.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Xylometazoline.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Xylometazoline.Approved, Withdrawn
HexamethoniumXylometazoline may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Xylometazoline.Approved
HexobarbitalThe metabolism of Xylometazoline can be increased when combined with Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Xylometazoline.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Xylometazoline.Approved
HydralazineHydralazine may increase the hypotensive activities of Xylometazoline.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved
IloprostIloprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
ImidaprilXylometazoline may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Xylometazoline.Approved
IndapamideIndapamide may increase the hypotensive activities of Xylometazoline.Approved
IndenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndoraminXylometazoline may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Xylometazoline.Approved
IproclozideIproclozide may increase the hypotensive activities of Xylometazoline.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Xylometazoline.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Xylometazoline.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Xylometazoline.Approved
IsradipineIsradipine may increase the hypotensive activities of Xylometazoline.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Xylometazoline.Approved, Investigational
JosamycinThe metabolism of Xylometazoline can be decreased when combined with Josamycin.Approved
KetanserinXylometazoline may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Xylometazoline.Approved, Investigational
KitasamycinThe metabolism of Xylometazoline can be decreased when combined with Kitasamycin.Experimental
LabetalolXylometazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineXylometazoline may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Xylometazoline.Approved
LisinoprilLisinopril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Xylometazoline.Approved
MacitentanXylometazoline may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineXylometazoline may increase the hypotensive activities of Manidipine.Approved
MebanazineMebanazine may increase the hypotensive activities of Xylometazoline.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Xylometazoline.Approved
MethohexitalThe metabolism of Xylometazoline can be increased when combined with Methohexital.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Xylometazoline.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Xylometazoline.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
MethylphenobarbitalThe metabolism of Xylometazoline can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Xylometazoline.Approved
MetolazoneMetolazone may increase the hypotensive activities of Xylometazoline.Approved
MetoprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineXylometazoline may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Xylometazoline.Experimental
MianserinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Mianserin.Approved
MibefradilMibefradil may increase the hypotensive activities of Xylometazoline.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Xylometazoline.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Xylometazoline.Approved, Investigational, Vet Approved
MilnacipranMilnacipran may decrease the antihypertensive activities of Xylometazoline.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Xylometazoline.Approved
MinaprineMinaprine may increase the hypotensive activities of Xylometazoline.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Xylometazoline.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Xylometazoline.Approved
MivacuriumXylometazoline may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Xylometazoline.Approved
MoexiprilMoexipril may increase the hypotensive activities of Xylometazoline.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Xylometazoline.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Xylometazoline.Vet Approved
MoxonidineXylometazoline may increase the hypotensive activities of Moxonidine.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Xylometazoline.Experimental
NadololXylometazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafcillinThe metabolism of Xylometazoline can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Xylometazoline.Approved
NaftopidilXylometazoline may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Xylometazoline.Approved
NebivololNebivolol may increase the hypotensive activities of Xylometazoline.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Xylometazoline.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Xylometazoline.Approved
NicorandilXylometazoline may increase the hypotensive activities of Nicorandil.Approved
NiguldipineXylometazoline may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineXylometazoline may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Xylometazoline.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Xylometazoline.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Xylometazoline.Approved
NitroprussideXylometazoline may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Xylometazoline.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Xylometazoline.Approved, Vet Approved
ObinutuzumabXylometazoline may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Xylometazoline.Withdrawn
OleandomycinThe metabolism of Xylometazoline can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Xylometazoline.Investigational
OpipramolOpipramol may decrease the antihypertensive activities of Xylometazoline.Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Xylometazoline.Approved
OxprenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Xylometazoline.Investigational
PargylinePargyline may increase the hypotensive activities of Xylometazoline.Approved
PenbutololXylometazoline may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Xylometazoline.Approved
PentobarbitalThe metabolism of Xylometazoline can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Xylometazoline.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Xylometazoline.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Xylometazoline.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Xylometazoline.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Xylometazoline.Withdrawn
PhenobarbitalThe metabolism of Xylometazoline can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Xylometazoline.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Xylometazoline.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Xylometazoline.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Xylometazoline.Approved, Vet Approved
PinacidilXylometazoline may increase the hypotensive activities of Pinacidil.Withdrawn
PindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PirlindolePirlindole may increase the hypotensive activities of Xylometazoline.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Xylometazoline.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Xylometazoline.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Xylometazoline.Approved, Investigational, Vet Approved
PractololXylometazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrazosinPrazosin may increase the hypotensive activities of Xylometazoline.Approved
PrimidoneThe metabolism of Xylometazoline can be increased when combined with Primidone.Approved, Vet Approved
PropranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
QuinaprilQuinapril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Xylometazoline.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Xylometazoline.Experimental
RamiprilRamipril may increase the hypotensive activities of Xylometazoline.Approved
RapacuroniumXylometazoline may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Xylometazoline.Approved
RemikirenRemikiren may increase the hypotensive activities of Xylometazoline.Approved
RescinnamineXylometazoline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Xylometazoline.Approved
RifabutinThe serum concentration of Xylometazoline can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Xylometazoline can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Xylometazoline can be decreased when it is combined with Rifapentine.Approved
RilmenidineXylometazoline may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatXylometazoline may increase the hypotensive activities of Riociguat.Approved
RituximabXylometazoline may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of Xylometazoline.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Xylometazoline.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Xylometazoline.Approved, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Xylometazoline.Experimental
SecobarbitalThe metabolism of Xylometazoline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Xylometazoline.Approved, Investigational, Vet Approved
SelexipagXylometazoline may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Xylometazoline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Xylometazoline.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Xylometazoline.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Xylometazoline.Approved, Investigational
SitaxentanXylometazoline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolithromycinThe metabolism of Xylometazoline can be decreased when combined with Solithromycin.Investigational
SotalolXylometazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Xylometazoline.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Xylometazoline.Approved
TadalafilTadalafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Xylometazoline.Approved
TelithromycinThe metabolism of Xylometazoline can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TemocaprilXylometazoline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Xylometazoline.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Xylometazoline.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Xylometazoline.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
ThiamylalThe metabolism of Xylometazoline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Xylometazoline can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Xylometazoline.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Xylometazoline.Approved
TiboloneXylometazoline may increase the hypotensive activities of Tibolone.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Xylometazoline.Withdrawn
TimololXylometazoline may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Xylometazoline.Approved
TolazolineTolazoline may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Xylometazoline.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Xylometazoline.Approved
TorasemideTorasemide may increase the hypotensive activities of Xylometazoline.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Xylometazoline.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Xylometazoline.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Xylometazoline.Approved
TravoprostTravoprost may increase the hypotensive activities of Xylometazoline.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
TrimazosinXylometazoline may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Xylometazoline.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Xylometazoline.Approved, Investigational
TrimipramineTrimipramine may decrease the antihypertensive activities of Xylometazoline.Approved
TroleandomycinThe metabolism of Xylometazoline can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Xylometazoline can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
UnoprostoneXylometazoline may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Xylometazoline.Approved
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Xylometazoline.Approved
VinpocetineXylometazoline may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Xylometazoline.Approved, Vet Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
External Links
ATC CodesS01GA53R01AB06R01AA07S01GA03
AHFS Codes
  • 52:32.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9866
Blood Brain Barrier+0.7293
Caco-2 permeable-0.5133
P-glycoprotein substrateSubstrate0.8254
P-glycoprotein inhibitor INon-inhibitor0.7469
P-glycoprotein inhibitor IINon-inhibitor0.8244
Renal organic cation transporterInhibitor0.6924
CYP450 2C9 substrateNon-substrate0.7815
CYP450 2D6 substrateNon-substrate0.531
CYP450 3A4 substrateNon-substrate0.5755
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9031
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9147
Ames testNon AMES toxic0.8306
CarcinogenicityNon-carcinogens0.9124
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1884 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9218
hERG inhibition (predictor II)Non-inhibitor0.745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
SprayNasal.01 L/L
SprayNasal10 mg/10mL
SprayNasal.05 mg/10mL
SprayNasal0.1 %
Solution; sprayNasal0.1 %
Solution; sprayNasal.1 %
SprayNasal.1 %
Solution / dropsNasal0.1 %
Solution / dropsOphthalmic
SprayNasal0.05 %
Solution / dropsNasal0.05 %
Liquid; sprayNasal.1 %
Solution / dropsNasal.05 %
SprayNasal.05 %
SprayNasal.015 mL/15mL
SolutionNasal0.1 %
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point132 °CPhysProp
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00893 mg/mLALOGPS
logP4.68ALOGPS
logP3.78ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)10.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity77.82 m3·mol-1ChemAxon
Polarizability29.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropanes
Direct ParentPhenylpropanes
Alternative Parents
Substituents
  • Phenylpropane
  • Imidolactam
  • 2-imidazoline
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91. [PubMed:8894610 ]
  2. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
  2. Petrusewicz J, Kaliszan R: Effect of imidazoline drugs on human blood platelet aggregation. Thromb Haemost. 1985 Dec 17;54(4):784-7. [PubMed:2868542 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735 ]
Comments
comments powered by Disqus
Drug created on April 25, 2010 17:54 / Updated on August 17, 2016 12:24